

October 29, 2026

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Subject: Outcome of the Board Meeting held on Thursday, October 29, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), we wish to inform you that the Board of Directors of the Company ("Board"), at its meeting held today i.e., **Thursday, October 29, 2026**, inter alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026, along with the Limited Review Reports thereon.

Pursuant to Regulation 33(3) of the SEBI Listing Regulations, the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, together with the Limited Review Reports issued by the Statutory Auditors of the Company, are attached herewith as **Annexure A**.

The aforesaid financial results are also being made available on the Company's website at <https://investor.thyrocare.com>.

The Board Meeting commenced at 2:35 P.M. and concluded at 03:42 P.M.

This is for your information and records.

Yours Faithfully,

For **Thyrocare Technologies Limited**,

Brijesh
Kumar

Brijesh Kumar

Company Secretary and Compliance Officer

Encl.: As above

Digitally signed by
Brijesh Kumar
Date: 2026.10.29
15:47:23 +05'30'



Price Waterhouse Chartered Accountants LLP

Review Report

To
The Board of Directors
Thyrocare Technologies Limited
D/37-1, TTC Industrial Area, MIDC Turbhe,
Navi Mumbai - 400 703.

1. We have reviewed the unaudited standalone financial results of Thyrocare Technologies Limited (the "Company") for the quarter ended September 30, 2026 and the year to date results for the period April 01, 2026 to September 30, 2026, and the notes that include the Unaudited Standalone Statement of Assets and Liabilities as on that date and the Unaudited Standalone Statement of Cash Flows for the half-year ended on that date which are included in the accompanying 'Unaudited Standalone Financial Results for the Quarter and Six Months Ended September 30, 2026' (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Price Waterhouse Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West), Mumbai – 400 028
T: +91(22) 66697510

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its Conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

The Board of Directors
Thyrocare Technologies Limited
Page 2 of 2

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. (a) The standalone financial results of the Company for the quarter ended September 30, 2025 and the year to date results for the period April 01, 2025 to September 30, 2025 were reviewed by another firm of chartered accountants who, vide their report dated October 14, 2025, expressed an unmodified conclusion on those financial results.

(b) The standalone financial statements of the Company for the year ended March 31, 2026 were audited by another firm of Chartered Accountants, who issued an unmodified opinion vide their report dated May 07, 2026.

Our conclusion is not modified in respect of these matters.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Nitin Khatri
Partner
Membership Number: 110282

UDIN: 26110282KNJSHG9091
Place: Mumbai
Date: October 29, 2026

THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: compliance@thyrocare.com

Corporate Identity Number: L86905MH2000PLC123882

Unaudited Standalone Financial Results for the Quarter and Six Months Ended September 30, 2026

(Rs. in Crores)

Sr. No	Particulars	Quarter ended			Six Month Ended		March 31, 2026 (Audited)
		September 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	
1	Revenue						
(a)	Revenue from operations	256.25	225.66	202.23	481.91	381.12	774.27
(b)	Other Income	2.94	3.51	2.28	6.45	6.24	13.39
	Total Revenue (a+b)	259.19	229.17	204.51	488.36	387.36	787.66
2	Expenses						
(a)	Cost of materials consumed	67.19	58.86	57.12	126.05	109.49	208.37
(b)	Purchase of stock-in-trade	0.33	0.03	0.21	0.36	0.28	1.09
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.25	0.24	0.04	0.49	0.19	(0.23)
(d)	Employee benefits expense	43.24	37.16	31.37	80.40	62.07	128.29
(e)	Finance cost	1.48	1.26	0.60	2.74	1.22	2.18
(f)	Depreciation and amortisation expense	12.50	11.23	9.70	23.73	18.65	51.17
(g)	Other expenses	59.20	53.76	44.58	112.96	83.66	180.42
	Total Expenses	184.19	162.54	143.62	346.73	275.56	571.29
3	Profit before exceptional items and income tax (1 - 2)	75.00	66.63	60.89	141.63	111.80	216.37
4	Exceptional Items (Refer note 4 below)	(9.17)	-	-	(9.17)	-	(5.97)
5	Profit after exceptional items and before tax (3 + 4)	65.83	66.63	60.89	132.46	111.80	210.40
6	Tax expense	(17.70)	(16.46)	(17.86)	(34.16)	(32.72)	(61.59)
7	Profit for the period/year (5 + 6)	48.13	50.17	43.03	98.30	79.08	148.81
8	Other comprehensive income						
	Items that will not be reclassified to profit or loss (net of tax)	(0.63)	0.48	0.07	(0.15)	(0.14)	0.22
9	Total comprehensive income for the period/ year (7 + 8)	47.50	50.65	43.10	98.15	78.94	149.03
	Paid-up equity share capital (Face value of Rs. 10/- each)	159.17	159.17	159.17	159.17	159.17	159.17
	Other equity						401.51
10	Earnings per share (of Rs. 10/- each) (Refer note 8):						
(a)	Basic (in Rs.)	3.03*	3.15*	2.70*	6.18*	4.97*	9.36
(b)	Diluted (in Rs.)	3.02*	3.14*	2.70*	6.16*	4.96*	9.34
	*not annualised						
	See accompanying notes to the Standalone Financial Results						



Particulars		As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
A	ASSETS		
i	Non-current assets		
(a)	Property, plant and equipment	124.64	113.56
(b)	Right-of-use assets	62.91	58.40
(c)	Capital-work-in progress	0.79	3.07
(d)	Investment properties	0.90	0.92
(e)	Goodwill	4.18	4.18
(f)	Other intangible assets	3.44	3.35
(g)	Investments accounted for using the equity method	20.00	20.00
(h)	Financial assets		
	i. Investments in Subsidiaries	158.52	167.04
	ii. Other financial assets	10.31	5.60
(i)	Deferred tax assets	16.52	12.71
(j)	Non-current tax assets (net)	-	4.15
(k)	Other non-current assets	1.45	2.42
	Total non-current assets	403.66	395.40
ii	Current assets		
(a)	Inventories	47.04	46.56
(b)	Financial assets		
	i. Investments	93.93	106.83
	ii. Trade receivables	81.34	69.53
	iii. Cash and cash equivalents	16.98	32.88
	iv. Bank balances other than (iii) above	42.55	29.75
	v. Other financial assets	4.39	1.21
(c)	Other current assets	24.53	29.05
	Total current assets	310.76	315.81
	TOTAL ASSETS	714.42	711.21
B	EQUITY AND LIABILITIES		
i	Equity share capital	159.17	159.17
ii	Other equity	399.13	401.51
	Total Equity	558.30	560.68
C	LIABILITIES		
i	Non-current liabilities		
(a)	Financial liabilities		
	i. Lease liabilities	43.43	38.32
	ii. Other financial liabilities	5.00	5.00
(b)	Provisions	12.95	11.79
	Total non-current liabilities	61.38	55.11
ii	Current liabilities		
(a)	Financial liabilities		
	i. Lease liabilities	9.77	9.86
	ii. Trade payables		
	Total outstanding dues to micro and small enterprises	5.56	5.76
	Total outstanding dues to creditors other than micro and small enterprises	44.49	49.37
	iii. Other financial liabilities	19.76	12.77
(b)	Contract Liabilities	8.41	10.60
(c)	Provisions	1.39	1.25
(d)	Current tax liabilities (net)	3.56	2.38
(e)	Other current liabilities	1.80	3.43
	Total current liabilities	94.74	95.42
	TOTAL LIABILITIES	156.12	150.53
	TOTAL EQUITY AND LIABILITIES	714.42	711.21



Particulars		For the Six months ended September 30, 2026 (Unaudited)	For the Six months ended September 30, 2025 (Unaudited)
A.	Cash flows from operating activities		
	Net profit before exceptional items and income tax	141.63	111.80
	Adjustments for:		
	Depreciation and amortisation	23.73	18.65
	Net gain on investments measured at fair value through profit and loss	(1.99)	1.80
	(Profit)/Loss on sale of short term investment	(1.50)	(4.84)
	(Profit)/Loss on sale of property, plant and equipment	-	(0.90)
	Provision for bad and doubtful debts	(3.03)	(2.88)
	Employee stock compensation expense	10.99	11.56
	Finance costs	2.74	1.22
	Interest income	(1.44)	(1.39)
	Operating profit before working capital changes	171.13	135.02
	Adjustments for:		
	Decrease/ (Increase) in Inventories	(0.48)	9.05
	Decrease/ (Increase) in Trade receivables	(8.78)	1.70
	Decrease in Other assets	0.34	5.82
	(Decrease) in Trade payables	(5.08)	(12.94)
	(Decrease)/ Increase in Other liabilities	3.13	(1.37)
	Increase in Provisions	1.31	0.01
	Cash generated from operations	161.57	137.29
	Income tax paid (net of refunds)	(32.67)	(18.50)
	Net cash flows generated from operating activities (A)	128.90	118.79
B.	Cash flows from investing activities		
	Payment for property, plant and equipment including capital work-in-progress and capital advances	(28.93)	(10.26)
	Proceeds from sale of property, plant and equipment	-	0.90
	Sale of current investments (net)	16.06	23.33
	Investment in joint venture and subsidiary	(0.75)	(1.06)
	Investment in term deposits	(12.78)	(2.46)
	Interest received	1.44	1.39
	Net cash (outflow)/generated from investing activities (B)	(24.96)	11.84
C.	Cash flows from financing activities		
	Payment towards principal portion of lease liabilities	(5.68)	(4.30)
	Payment towards interest portion of lease liabilities	(2.74)	(1.22)
	Dividend paid to the shareholders	(111.42)	(111.24)
	Net cash used in financing activities (C)	(119.84)	(116.76)
	Net (Decrease)/Increase in Cash and cash equivalents (A+B+C)	(15.90)	13.87
	Cash and cash equivalents at the beginning of the period	32.88	15.18
	Cash and cash equivalents at the end of the period	16.98	29.05

Notes :

- 3 The above standalone unaudited financial results of the Company were reviewed and recommended by the Audit Committee on October 29, 2026 and subsequently approved by the Board of Directors at its meeting held on October 29, 2026. The statutory auditors of the Company have expressed an unmodified conclusion on the standalone unaudited financial results for the quarter and six months ended 30 September 2026.
- 4 Based on the latest valuation report obtained, the management has reassessed the recoverable amount of its investment in NHL and has recognized an additional impairment loss of Rs. 9.17 crore during the quarter ended September 30, 2026 and the same has been presented as an exceptional item in the financial results.



- 5 The Board of Directors of the Company, at its meeting held on September 21, 2026, approved the proposed sale of the Company's entire shareholding in Nueclear Healthcare Limited ("NHL"), a wholly owned subsidiary, for an aggregate consideration comprising cash and Compulsorily Convertible Preference Shares ("CCPS") amounting to approximately Rs.141.40 crore, subject to working capital adjustments in accordance with the terms of the proposed transaction. The proposed transaction is subject to requisite shareholders' approval, including approval of the majority of the public shareholders. Accordingly, the Company issued a Postal Ballot Notice seeking shareholders' approval for the proposed transaction, with the e-voting period commencing on September 30, 2026 and ending on October 29, 2026.

As at September 30, 2026, the requisite shareholders' approval remained pending. Management has assessed that such approval represents a substantive condition to the proposed transaction and, accordingly, the criteria for classification as held for sale under Ind AS 105, Non-current Assets Held for Sale and Discontinued Operations, were not met as at September 30, 2026. Consequently, the Company has not classified its investment in NHL as held for sale in the financial results for the period ended September 30, 2026.

- 6 During the quarter ended September 30, 2026, the Company has forfeited 6,649 equity stock options and no equity stock options respectively granted to employees under Employee Stock Option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable.
- 7 In accordance with Ind AS 108 'Operating Segments', segment information has been given in the unaudited consolidated financial results of the Group.
- 8 The earning per share and paid up equity share capital in respect of quarter and six month ended September 30, 2025 has been restated considering the allotment of bonus shares and adjustment in respect of outstanding stock options, in line with the requirements of Ind AS 33 "Earnings Per Share".

For and on behalf of Board of Directors



Rahul Guha
Managing Director
DIN - 09588432

Navi Mumbai, 29 October 2026

Price Waterhouse Chartered Accountants LLP

Review Report

To

The Board of Directors

Thyrocare Technologies Limited

D/37-1, TTC Industrial Area, MIDC Turbhe,

Navi Mumbai - 400 703.

1. We have reviewed the unaudited consolidated financial results of Thyrocare Technologies Limited (the "Holding Company"), its subsidiaries (the Holding Company and its subsidiaries) hereinafter referred to as the "Group"), and its share of the net profit after tax and total comprehensive income of its associate company for the quarter ended September 30, 2026 and the year to date results for the period April 01, 2026 to September 30, 2026, and the notes that include the Unaudited Consolidated Statement of Assets and Liabilities as on that date and the Unaudited Consolidated Statement of Cash Flows for the half-year ended on that date which are included in the accompanying 'Unaudited Consolidated Financial Results for the Quarter and Six Months Ended September 30, 2026' (the "Statement"). The Statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialed by us for identification purposes.
2. This Statement, which is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



Price Waterhouse Chartered Accountants LLP, 252, Veer Savarkar Marg, Shivaji Park, Dadar (West), Mumbai - 400 028
T: +91(22) 66697510

Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110 002

Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its Conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/N500016 (ICAI registration number before conversion was 012754N)

Price Waterhouse Chartered Accountants LLP

The Board of Directors
Thyrocare Technologies Limited
Page 2 of 3

4. The Statement includes the results of the following entities:
- Thyrocare Technologies Limited (Holding Company)
 - Nuclear Healthcare Limited (Subsidiary)
 - Pulse Hitech Health Services (Ghatkopar) LLP (Subsidiary)
 - Think Health Diagnostic Private Limited (Subsidiary)
 - Thyrocare Laboratories (Tanzania) Limited (Subsidiary)
 - Equinox Labs Private Limited (Associate)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results include the interim financial results of three subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total assets of Rs. 12.16 Crores and net assets of Rs. 0.24 Crores as at September 30, 2026 and total revenue of Rs. 3.70 Crores and Rs. 6.90 Crores and total net loss after tax and total comprehensive loss of Rs. 0.35 Crores and Rs. 1.19 Crores for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026, respectively and cash used (net) of Rs 1.02 crores for the period April 01, 2026 to September 30, 2026, as considered in the unaudited consolidated financial results. The unaudited consolidated financial results also include the Group's share of total net profit after tax and total comprehensive income of Rs. 0.80 Crores and Rs. 1.51 Crores for the quarter ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026, respectively, as considered in the unaudited consolidated financial results, in respect of one associates based on their interim financial results, which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.



Price Waterhouse Chartered Accountants LLP

The Board of Directors
Thyrocare Technologies Limited
Page 3 of 3

7. (a) The comparative figures of the Group as set out in the Statement for the quarter ended September 30, 2025 and the year to date results for the period April 01, 2025 to September 30, 2025 were reviewed by another firm of Chartered Accountants who, vide their report dated October 14, 2025, expressed an unmodified conclusion on the same.

(b) The consolidated financial statements of the Company for the year ended March 31, 2026, were audited by another firm of chartered accountants under the Companies Act, 2013 who, vide their report dated May 07, 2026, expressed an unmodified opinion on those financial statements.

Our conclusion on the Statement is not modified in respect of the above matters.

For Price Waterhouse Chartered Accountants LLP
Firm Registration Number: 012754N/N500016



Nitin Khatri
Partner
Membership Number : 110282

UDIN : 26110282BADAEG7946
Place: Mumbai
Date: October 29, 2026

THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409

Website: www.thyrocare.com

E-mail: compliance@thyrocare.com

Corporate Identity Number: L86905MH2000PLC123882

Unaudited Consolidated Financial Results for the Quarter and Six Months Ended September 30, 2026

		Quarter ended			Six months ended		(Rs. in Crores)
Sr. No	Particulars	September 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	March 31, 2026 (Audited)
1	Revenue						
(a)	Revenue from operations	270.81	240.02	216.53	510.83	409.56	829.04
(b)	Other Income	3.63	4.15	3.05	7.78	7.70	16.99
	Total Revenue (a+b)	274.44	244.17	219.58	518.61	417.26	846.03
2	Expenses						
(a)	Cost of materials consumed	69.26	61.88	59.81	131.14	115.22	218.71
(b)	Purchase of stock-in-trade	0.33	0.03	0.21	0.36	0.28	1.09
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.25	0.25	0.04	0.50	0.19	(0.23)
(d)	Employee benefits expense	45.21	39.61	33.23	84.82	66.23	138.06
(e)	Finance cost	1.57	1.35	0.59	2.92	1.37	2.80
(f)	Depreciation and amortisation expense	13.52	12.49	11.51	26.01	22.92	58.58
(g)	Other expenses	66.47	60.98	51.89	127.45	98.52	209.37
	Total Expenses	196.61	176.59	157.28	373.20	304.73	628.38
3	Profit before exceptional items, share of profit of associate and income tax (1 - 2)	77.83	67.58	62.30	145.41	112.53	217.65
4	Exceptional Items (Refer note 5 below)	(44.98)	-	-	(44.98)	-	(6.16)
5	Profit before share of profit of associate and income tax (3 + 4)	32.85	67.58	62.30	100.43	112.53	211.49
6	Share of profit of associate	0.80	0.71	0.28	1.51	0.53	1.39
7	Profit before tax (5 + 6)	33.65	68.29	62.58	101.94	113.06	212.88
8	Tax expense	(18.43)	(16.96)	(14.77)	(35.39)	(26.96)	(50.03)
9	Profit for the period/year (7 + 8)	15.22	51.33	47.81	66.55	86.10	162.85
10	Other comprehensive income						
	Items that will not be reclassified to profit or loss (net of tax)	(0.62)	0.39	0.09	(0.23)	(0.14)	0.38
11	Total comprehensive income for the period/ year (9+10)	14.60	51.72	47.90	66.32	85.96	163.23
12	Profit/ (Loss) attributable to :						
(a)	Owners of the company	15.89	52.19	47.99	68.08	86.92	163.04
(b)	Non-controlling interest	(0.67)	(0.86)	(0.18)	(1.53)	(0.82)	(0.19)
		15.22	51.33	47.81	66.55	86.10	162.85
13	Total comprehensive income attributable to :						
(a)	Owners of the company	15.27	52.58	48.08	67.85	86.78	163.42
(b)	Non-controlling interest	(0.67)	(0.86)	(0.18)	(1.53)	(0.82)	(0.19)
		14.60	51.72	47.90	66.32	85.96	163.23
	Paid-up equity share capital (Face value of Rs. 10/- each)	159.17	159.17	159.17	159.17	159.17	159.17
	Other equity						426.33
14	Earnings per share (of Rs. 10/- each) (Refer Note 9) :						
(a)	Basic (in Rs.)	0.96*	3.22*	3.00*	4.18*	5.41*	10.23
(b)	Diluted (in Rs.)	0.95*	3.21*	3.00*	4.16*	5.40*	10.20
	*not annualised						
	See accompanying notes to the Consolidated Financial Results						



Particulars		As at September 30, 2026 (Unaudited)	As at March 31, 2026 (Audited)
A	ASSETS		
i	Non-current assets		
(a)	Property, plant and equipment	155.87	145.08
(b)	Right-of-use assets	66.47	60.54
(c)	Capital-work-in progress	0.88	3.06
(d)	Goodwill	63.23	108.21
(e)	Other intangible assets	3.54	3.49
(f)	Investments accounted for using the equity method	26.65	25.14
(g)	Financial assets		
	i. Other financial assets	11.22	6.66
(h)	Deferred tax assets	18.53	15.66
(i)	Non-current tax assets (net)	0.51	4.31
(j)	Other non-current assets	1.73	2.78
	Total non-current assets	348.63	374.93
ii	Current assets		
(a)	Inventories	48.72	48.46
(b)	Financial assets		
	i. Investments	141.69	151.50
	ii. Trade receivables	89.34	73.88
	iii. Cash and cash equivalents	21.90	38.32
	iv. Bank balances other than (iii) above	42.55	29.84
	v. Other financial assets	5.27	2.25
(c)	Other current assets	27.03	28.04
	Total current assets	376.50	372.29
	TOTAL ASSETS	725.13	747.22
B	EQUITY AND LIABILITIES		
i	Equity share capital	159.17	159.17
ii	Other equity	394.26	426.33
iii	Non-controlling interests	(1.01)	0.52
	Total Equity	552.42	586.02
C	LIABILITIES		
i	Non-current liabilities		
(a)	Financial liabilities		
	i. Lease liabilities	48.36	39.18
(b)	Provisions	13.38	12.11
	Total non-current liabilities	61.74	51.29
ii	Current liabilities		
(a)	Financial liabilities		
	i. Lease liabilities	8.52	11.51
	ii. Trade payables		
	Total outstanding dues to micro and small enterprises	5.65	5.98
	Total outstanding dues to creditors other than micro and small enterprises	56.85	59.39
	iii. Other financial liabilities	21.82	14.45
(b)	Contract Liabilities	8.46	10.69
(c)	Provisions	1.47	1.46
(d)	Current tax liabilities (net)	3.76	4.05
(e)	Other current liabilities	4.44	2.38
	Total current liabilities	110.97	109.91
	TOTAL LIABILITIES	172.71	161.20
	TOTAL EQUITY AND LIABILITIES	725.13	747.22



Particulars		For the Six months ended September 30, 2026 (Unaudited)	For the Six months ended September 30, 2025 (Unaudited)
A.	Cash flows from operating activities		
	Net profit before exceptional items and income tax	145.41	112.53
	Adjustments for:		
	Depreciation and amortisation	26.01	22.92
	(Profit)/Loss on sale of short term investment	(3.33)	0.77
	(Profit)/Loss on sale of property, plant and equipment	-	(0.90)
	Profit on sale of short term investment	(1.50)	(4.84)
	Provision for bad and doubtful debts	(2.93)	(2.65)
	Finance costs	2.92	1.37
	Gain on termination of lease	(0.22)	-
	Employee stock compensation expense	11.51	11.92
	Interest income	(1.15)	(1.39)
	Operating profit before working capital changes	176.72	139.73
	Adjustments for:		
	Decrease/ (Increase) in Inventories	(0.27)	8.62
	Decrease/ (Increase) in Trade receivables	(12.53)	0.16
	(Increase) in Other assets	(2.50)	(0.04)
	(Decrease) in Trade payables	(2.64)	(10.20)
	(Decrease) Increase in Other liabilities	5.75	7.34
	Increase in Provisions	1.29	0.01
	Cash generated from operations	165.82	145.62
	Income tax paid (net of refunds)	(33.00)	(18.50)
	Net cash flows generated from operating activities (A)	132.82	127.12
B.	Cash flows from investing activities		
	Payment for property, plant and equipment including capital work-in-progress and capital advances	(33.20)	(15.79)
	Proceeds from sale of property, plant and equipment	-	0.90
	Sale of current investments (net)	14.64	19.83
	Investment in joint venture and subsidiary	-	0.84
	Investment in term deposits	(12.98)	(2.46)
	Interest received	1.15	1.39
	Net cash (used)/generated from investing activities (B)	(30.39)	4.71
C.	Cash flows from financing activities		
	Proceeds from issue of equity shares	0.00	0.01
	Payment towards principal portion of lease liabilities	(4.51)	(5.37)
	Payment towards interest portion of lease liabilities	(2.92)	(1.37)
	Dividend paid to the shareholders	(111.42)	(111.24)
	Net cash used in financing activities (C)	(118.85)	(117.97)
	Net (Decrease)/Increase in Cash and cash equivalents (A+B+C)	(16.42)	13.86
	Cash and cash equivalents at the beginning of the period	38.32	17.68
	Cash and cash equivalents at the end of the period	21.90	31.54



Notes:

3 Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker evaluates the Group's Performance. The Holding Company has identified business segments as its primary segments. The Holding Company recognizes its diagnostic testing services activity and imaging services including manufacturing of radiopharmaceuticals activity as its primary business segments. Diagnostic testing services operations predominantly consists of providing laboratory testing services to its customers. Imaging services segment represents PET-CT scan and sale of radio pharmaceuticals used in imaging services. Others represents trading and other related business activities. The accounting principles used in the preparation of the financial statements are consistently applied to record revenue and expenditure in individual segments.

(Rs. in crores)

Particulars	Quarter ended			Six months ended		Year ended March 31, 2026 (Audited)
	September 30, 2026 (Unaudited)	June 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	September 30, 2026 (Unaudited)	September 30, 2025 (Unaudited)	
Segment Revenue						
Diagnostic Testing Services	256.74	226.21	201.56	482.95	379.89	772.53
Imaging Services	13.55	13.48	14.20	27.03	28.24	53.14
Others	0.52	0.33	0.77	0.85	1.43	3.37
Total	270.81	240.02	216.53	510.83	409.56	829.04
Less : Intersegment Revenue	-	-	-	-	-	-
Revenue from Operations	270.81	240.02	216.53	510.83	409.56	829.04
Segment Results before tax exceptional items, share of loss of associate and income tax						
Diagnostic Testing Services	71.52	61.90	56.95	133.42	101.80	197.48
Imaging Services	2.09	1.26	1.80	3.35	2.07	0.67
Others	0.59	0.27	0.50	0.86	0.96	2.51
Total	74.20	63.43	59.25	137.63	104.83	200.66
Add : Unallocable income net off other unallocable expenditure	3.63	4.15	3.05	7.78	7.70	16.99
Total Profit before exceptional items, share of loss of associate and income tax	77.83	67.58	62.30	145.41	112.53	217.65
Exceptional items	(44.98)	-	-	(44.98)	-	(6.16)
Share of profit/ (loss) of associate and joint venture	0.80	0.71	0.28	1.51	0.53	1.39
Profit before tax	33.65	68.29	62.58	101.94	113.06	212.88
Segment assets						
Diagnostic Testing Services	518.80	586.12	457.73	518.80	457.73	514.08
Imaging Services	161.16	203.94	185.30	161.16	185.30	192.34
Others	-	-	-	-	-	-
Unallocated	45.17	43.04	37.18	45.17	37.18	40.80
	725.13	833.10	680.21	725.13	680.21	747.22
Segment Liabilities						
Diagnostic Testing Services	159.07	175.89	121.51	159.07	121.51	147.35
Imaging Services	11.26	11.87	13.65	11.26	13.65	11.47
Others	-	-	-	-	-	-
Unallocated	2.38	2.38	10.94	2.38	10.94	2.38
	172.71	190.14	146.10	172.71	146.10	161.20

4 The above consolidated unaudited financial results of the Holding Company were reviewed and recommended by the Audit Committee on October 29, 2026 and subsequently approved by the Board of Directors at its meeting held on October 29, 2026. The statutory auditors of the Company have expressed an unmodified conclusion on the standalone unaudited financial results for the quarter and six months ended 30 September 2026.

5 Based on the latest valuation report obtained, the management has reassessed the recoverable amount of its investment in NHL and has recognized an additional impairment loss of Rs. 44.98 crore during the quarter ended September 30, 2026 and the same has been presented as an exceptional item in the financial results.

6 The Board of Directors of the Holding Company, at its meeting held on September 21, 2026, approved the proposed sale of the Holding Company's entire shareholding in Nueclear Healthcare Limited ("NHL"), a wholly owned subsidiary, for an aggregate consideration comprising cash and Compulsorily Convertible Preference Shares ("CCPS") amounting to approximately Rs.141.40 crore, subject to working capital adjustments in accordance with the terms of the proposed transaction. The proposed transaction is subject to requisite shareholders' approval, including approval of the majority of the public shareholders. Accordingly, the Holding Company issued a Postal Ballot Notice seeking shareholders' approval for the proposed transaction, with the e-voting period commencing on September 30, 2026 and ending on October 29, 2026.

As at September 30, 2026, the requisite shareholders' approval remained pending. Management has assessed that such approval represents a substantive condition to the proposed transaction and, accordingly, the criteria for classification as held for sale under Ind AS 105, Non-current Assets Held for Sale and Discontinued Operations, were not met as at September 30, 2026. Consequently, the Holding Company has not classified its investment in NHL as held for sale in the financial results for the period ended September 30, 2026.

7 These unaudited consolidated financial results have been prepared in compliance with Ind AS as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting pronouncements generally accepted in India, to the extent applicable.



- 8 During the quarter ended September 30, 2026, the Group has forfeited 6,649 equity stock options granted to employees under employees stock option schemes but not vested on account of discontinuance of services of these employees, which has been added back to the pool and the same would be available for subsequent distribution subject to statutory rules and regulations, as applicable.
- 9 The earning per share and paid up equity share capital in respect of quarter and six month ended September 30, 2025 has been restated considering the allotment of bonus shares and adjustment in respect of outstanding stock options, in line with the requirements of Ind AS 33 "Earnings Per Share".



For and behalf of Board of Directors

A handwritten signature in blue ink, appearing to read "Rahul Guha".

Rahul Guha
Managing Director

DIN - 09588432
Navi Mumbai, 29 October 2026